| abstract |
To reduce or treat osteoporosis or postmenopausal symptoms, or other diseases affected by estrogen receptor activity, and other diseases that respond well to DHEA treatment but require a high ratio of estrogen effects to androgenic effects. Androast-5-ene-3β, 17β-diol is used. Combination therapy as pharmaceutical compositions and kits for providing the claimed methods and combinations of active ingredients. |